

*Advances in Diabetes Care:  
Understanding Insulin Resistance and  
Metabolic Syndrome*

This supplement to *The American Journal of Managed Care* includes a continuing education article that has been developed under the direction of and peer reviewed by Christopher D. Saudek, MD, for CME accreditation, and by Glen E. Farr, PharmD, for CPE accreditation.

---

FACULTY

**Anne Peters Harmel, MD**  
Director, Clinical Diabetes Program  
Professor of Clinical Medicine  
University of Southern California  
Keck School of Medicine  
Los Angeles, California

**David M. Kendall, MD**  
Chief of Clinical Services and  
Medical Director  
International Diabetes Center  
Associate Professor of Medicine  
University of Minnesota  
Minneapolis, Minnesota

DISCLOSURE STATEMENT

It is the policy of the Johns Hopkins University School of Medicine to ensure fair balance, independence, objectivity, and scientific rigor in all sponsored programs. All faculty participating in a continuing medical education activity are expected to disclose to the audience any relationship with a pharmaceutical or equipment company that might pose potential, apparent, or real conflict of interest with regard to their contribution to the program.

It is also the policy of *The American Journal of Managed Care* to have all faculty who participate in programs sponsored by corporate organizations disclose any real or apparent conflicts of interest.

These participants have declared the following affiliations with corporate organizations:

■ **Anne Peters Harmel, MD**  
*Consultant To/Honoraria*  
*Support From:*  
Takeda/Eli Lilly

■ **David M. Kendall, MD**  
*Clinical Investigator For/Consultant To/  
Honoraria Support From:*  
Pfizer  
Bristol-Myers Squibb  
Eli Lilly  
GlaxoSmithKline  
Aventis  
Novartis  
Sensys Medical  
Therasense  
Takeda  
NovoNordisk

Signed disclosures are on file at the offices of *The American Journal of Managed Care*, Jamesburg, New Jersey.

Discussion of off-label uses of drugs or devices includes combined statin-fibrate therapy, metformin for diabetes prevention, and glitazones for cardiovascular disease protection and diabetes prevention.